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CALCULATING PULMONARY-MODE-LETHALITY RISK AVOIDANCE
ASSOCIATED WITH RADIONUCLIDE DECORPORATION COUNTERMEASURES
RELATED TO A RADIOLOGICAL TERRORISM INCIDENT
Bobby R. Scott   Lovelace Respiratory Research Institute, Albuquerque, NM
 Planning for and managing radiological terrorism incidents that involve the release of
radionuclides from a dirty bomb requires considering the potential lifesaving impact of
protective radionuclide decorporation countermeasures (e.g., lung lavage). Lung lavage
therapy could prevent deaths via the pulmonary mode (which involves radiation pneu-
monitis and fibrosis) by reducing the radiation dose to the lung from inhaled radionu-
clides. The risk avoidance (RAV) assessment framework introduced in a related paper is
used to evaluate the pulmonary-lethality-mode RAV due to lung lavage and the associated
risk avoidance proportion (RAP) for hypothetical inhalation-exposure scenarios. The
lethality RAV is a measure (on a scale from 0 to 1) of the actual risk reduction associated
with the applied protective countermeasures. The lethality RAP is the lethality RAV divid-
ed by the lethality risk when no protective countermeasures are employed and is a useful
measure of the efficacy of the countermeasures applied. Examples of pulmonary-mode
lethality RAV and RAP calculations are presented for hypothetical scenarios involving lung
lavage to remove beta and/or gamma-emitting radionuclides that are inhaled in highly
insoluble forms. The approach presented could be used to develop optimal schemes for
applying lung lavage therapy following a terrorist incident involving a dirty bomb.
Keywords: Risk, radionuclide, lethality, decorporation, countermeasures
INTRODUCTION
Recent terrorist actions throughout the world underscore the grow-
ing threat of radiological terrorism (DHS 2003; CDC 2005; DHHS 2009).
This has stimulated research on and development of medical counter-
measures for protecting humans against radiation harm, including harm
resulting from use by terrorist of a radioactivity dispersal device (RDD)
such as a dirty bomb.
During a radiological terrorist incident radionuclides could be
inhaled (e.g., after a dirty bomb detonation). Inhaling large quantities of
radionuclides could lead to lives lost among the general public from radi-
ation-induced deterministic effects that evolve over time. Deterministic
effects are threshold-type effects that include lethal damage to the lung
(e.g., radiation-pneumonitis-related). The threshold dose for lethal dam-
age varies for different individuals and depends on how dose rate
changes over time (Scott and Hahn 1989). The time to deliver a lethal
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dose increases as dose rate decreases. For long-lived radionuclides
inhaled in highly insoluble forms, the accumulation of a lethal radiation
dose may require more than a year after inhaling the radioactive materi-
al. The effective management of dirty bomb incidents requires careful
planning that includes considering the impact of radionuclide decorpo-
ration (removal from the body) countermeasures that could be employed
to reduce the radiation dose and associated risk of harm to first respon-
ders, members of the general public, and others.
Employing lung lavage (bronchoalveolar) is a possible countermea-
sure to remove excess radioactivity from the respiratory tract in the case
of inhalation exposure to airborne radionuclides resulting from a dirty
bomb incident (Nolibé et al. 1989; Muggenburg et al. 1990; Breitenstein
2003). The removal leads to a reduction in the committed radiation dose
(the dose that builds up over time) and also may reduce the risk of radi-
ation-induced harm depending on the endpoint considered and residual
radiation dose (Scott 2005). Pharmaceutical and other products are also
being developed for possible employment as radioprotectors and as
decorporating agents to facilitate removing radionuclides from the body
after uptake into the systemic circulation. However, the focus here is on sce-
narios involving inhalation of highly insoluble aerosols that mainly irradiate the
respiratory tract. A related paper addresses ingestion (via a liquid) of high-
ly soluble forms of beta and/or gamma-emitting radionuclides that
deposit in the skeleton and irradiate the radiosensitive bone marrow
(Scott 2009).
The related paper (Scott 2009) introduces health risk assessment
(HRA) tools that facilitate planning for and managing radiological ter-
rorism incidents such as those that involve an RDD. The indicated HRA
tools include analytical functions for evaluating the lethality risk avoid-
ance (RAV) due to protective countermeasures and the risk avoidance
proportion (RAP) (RAV divided by the lethality risk in the absence of pro-
tective countermeasures). These hazard-function (HF) model-based tools
are applied in this paper to hypothetical scenarios that involve humans
exposed by inhalation to highly insoluble beta- and/or gamma-emitting
aerosols released from a dirty bomb. Examples of pulmonary-mode-
lethality RAV and RAP calculations are provided. The pulmonary mode of
lethality (from severe damage to the lung) is considered to be related to
radiation pneumonitis and fibrosis (Scott and Hahn 1989).
The hypothetical scenarios considered in the main text involve cir-
cumstances where the low linear-energy-transfer (LET) beta/gamma
radiation dose rate to the lung (critical target considered) decreases as a
single, negative-exponential function of time. The single negative-expo-
nential characterization is used for illustrative purposes to facilitate
understanding of how to evaluate the lethality RAV and RAP. More gen-
eral relationships that apply to any monotonically decreasing (i.e., steadi-
B. R. Scott
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ly decreasing) dose-rate pattern are presented in the Appendix.
Information is also provided in the main text about how to address dose
rates that initially increase over time and then steadily decrease. 
METHODS
Evaluating Pulmonary Mode Lethality RAV and RAP
Lethality risks are evaluated based on the HF model (Scott 2004)
using the approach described in the cited related paper (Scott 2009). For
the HF model and for the pulmonary mode of death, the risk function R
(i.e., individual probability of radiation-induced lethal damage to the
lung) is given as a function of lethality-mode-specific hazard, Hpul (a
cumulative hazard function for the pulmonary mode) and survival prob-
ability, S, by (Scott and Hahn 1989):
R = 1 – S =1 – exp(–Hpul). (1)
The pulmonary-model lethality hazard Hpul can be evaluated based
on the following equation: 
Hpul = [ln(2)]X
V, (2)
where V (>0) is the shape parameter that determines the steepness of the
sigmoid dose-response curve for the lethality risk; X is the normalized dose
in units of the lethality-mode-specific, median-lethal absorbed dose D50.
The value X = 1 corresponds to the median lethal absorbed dose D50,
which increases as the dose rate decreases. Absorbed dose to the lung is
determined by total radiation energy imparted to the lung divided by the
mass of the lung and has units such as gray (Gy). A gray equals 1 joule per
kilogram of tissue. For high dose rate exposure, D50 has been estimated to
be 10 Gy (central estimate) (Scott and Hahn 2009).
The normalized dose (i.e., X) is quite useful for addressing subtle
changes in dose rate pattern as occur with radionuclide decorporation
therapy. For example, the normalized dose increment that occurs before
applying lung lavage can be evaluated and added to the additional nor-
malized dose increment that occurs after application of the procedure.
Risk is then evaluated based on the sum of the two normalized dose incre-
ments (Scott 2009). Evaluating the normalized dose X requires a func-
tional relationship between D50 and the organ-specific radiation absorbed
dose rate y when held at a given value. For the pulmonary mode of lethal-
ity, a functional relationship that has been found to be adequate is given
by the following equation (Scott and Hahn 2009):
D50(y) = (θ1/y) + θ∞. (3)
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Equation 3 was developed for exposure to low LET beta and/or gamma
radiation but was also applied to high-LET alpha radiation via adjusting
model parameters (Scott 2007) or via using RBE-weighted dose (Scott
and Peterson 2003). For the pulmonary mode of death (radiation pneu-
monitis and fibrosis related) and for internal low-LET beta/gamma radi-
ation, central estimates for HF model parameters are V = 5, θ
∞
= 10 Gy,
and θ1 = 30 Gy2/h (Scott and Hahn 1989). Uncertainty related to these
parameters (i.e., parameter uncertainty) can be addressed via subjective
lower and upper bounds (Scott and Hahn 1989). Subjective lower and
upper bounds for V are 4 and 6, respectively; for θ
∞
, 8 and 12 Gy, respec-
tively; for θ1, 15 and 45 Gy2/h, respectively. The impact on risk assessment
reliability of model parameter uncertainty was address in other publica-
tions (USNRC/CEC 1997; Scott and Peterson 2003; Scott 2007).
Analytical Solution for X for Single, Negative-Exponential-Decaying 
Dose Rate
The following analytical solution applies for a single negative-expo-
nential-decaying dose-rate pattern with initial dose rate A and decay
parameter λ (Scott and Dillehay 1990; Scott 2009): 
X {t, A} = Xmax{t, A} – Q {t, A}. (4)
The terms on the right-hand side of Equation 4 represent the following: 
Xmax{t, A} = D {t, A})/θ∞ (5)
and
Q {t, A} = (θ1 ln{[Aθ∞ + θ1]/[Aθ∞ exp(–λt) + θ1]})/λθ∞2. (6)
The function D {t, A} is the exposure-time-dependent radiation absorbed
dose to the target organ at exposure time t and is evaluated as (A/λ)[1 –
exp(–λt)] for the dose rate pattern to the lung considered here. The
parameter λ relates to the effective retention halftime (T1/2) of the
radionuclide in the target organ according to the equation λ =
ln(2)/T1/2. Exposure scenarios considered here involve a single, brief inhalation
exposure episode rather than chronic intake.
The function Q {t, A} is called the normalized dose adjustment
(NORDA) (Scott 2009). The adjustment is due to the body’s protective
measures (e.g., repopulation of lost lung cells and repair of DNA dam-
age) that come into play when the dose rate is low, making the normal-
ized dose shrink from its maximum value Xmax{t, A} that occurs when dose
rate remains high. An equation analogous to Equation 4 is utilized in the
B. R. Scott
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Appendix to obtain results for application to any type of dose rate pattern
that monotonically decreases with time. 
Asymptotic Solution for Normalized Dose
Over time and for a single, negative-exponential-decaying dose-rate
pattern to the lung, X {t, A} will approach an asymptotic value X
∞
{A} (i.e.,
asymptotic normalized dose) which can be obtained by taking the limit of X {t,
A} (based on Equation 4) as t → ∞. This limit is given by the following
(Scott 2009):
X
∞
{A} = (D
∞
{A}/θ
∞
) + Q
∞
{A}. (7)
where:
D
∞
{A} = A/λ (8)
and
Q
∞
{A} = [θ1 ln{(Aθ∞ + θ1)/(θ1)}]/λθ∞2. (9)
The term Q
∞
{A} is the maximum value for the NORDA for a single, nega-
tive-exponential-decaying dose-rate pattern. The dose X
∞
{A} when evalu-
ated according to Equation 7 will be linearly related to T1/2 (Scott 2009).
RESULTS AND DISCUSSION
Time Period over which Radiation Dose Should Be Evaluated
Plotting X {t, A}/X
∞
{A} vs. t/T1/2 (normalized time in units of T1/2) is a
useful way of determining the period over which radiation dose to the
lung should be evaluated when assessing lethality risks (or risk avoidance)
for single, negative-exponential-decaying dose-rate patterns (Scott 2009).
This period will depend on the initial dose rate A, T1/2 (which relates to
λ), and parameters θ
∞
and θ1. The ratio X {t, A}/X∞{A} will increase as
t/T1/2 increases and eventually approach the asymptotic value of 1.0
(Scott 2009). The lethality risk R will be expected to increase so long as
X {t, A}/X
∞
{A} increases. 
Table 1 shows calculated values (rounded) of X {t, A}/X
∞
{A} vs. t/T1/2
for different initial dose rates (A = 0.01, 0.02, 0.04, 0.06, 0.08, or 0.1
Gy/h) to the lung of humans after a single inhalation exposure to
beta/gamma-emitting radionuclides in highly insoluble forms when dose
rate decreases as a single-negative-exponential function of time. Results
were obtained based on T1/2 = 2000 d. In each case considered, a value of
t/(T1/2) = 2.2 approximates the normalized time at which 95% of the infi-
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nite normalized dose (i.e., X
∞
{A}) is achieved. However, for lower initial
dose rates, different results may occur. Based on the results presented in
Table 1, most of the lethality risk accumulation would be expected to
have occurred by the time t for which t/T1/2 = 4. This time is given by
4T1/2 which for example would be 4000 d after radionuclide intake when
T1/2 = 1000 d.
For multiple negative exponential decaying dose-rate patterns, T1/2
can be evaluated based on the long-term retention component. However,
the more involved procedure presented in the Appendix is then needed
for evaluating the normalized dose.
Evaluating Lethality Risk Avoidance due to Lung Lavage
Scenarios considered here involve a single application of lung lavage
to remove a deposited radionuclide inhaled and deposited as a result of
B. R. Scott
88
TABLE 1. Expected ratio X {t, A}/X
∞
{A} vs. t/(T1/2) for the pulmonary mode of death after single
inhalation exposure to highly-insoluble beta/gamma-emitting radionuclides when dose rate
decreases as a single-negative-exponential function of time.
Initial Dose Rate (Gy/h)
t/(T1/2) 0.01 0.02 0.04 0.06 0.08 0.1
0 0 0 0 0 0 0
0.2 0.24 0.24 0.24 0.24 0.24 0.24
0.4 0.43 0.43 0.43 0.42 0.42 0.42
0.6 0.57 0.57 0.56 0.56 0.56 0.56
0.8 0.67 0.67 0.67 0.67 0.67 0.67
1 0.75 0.75 0.75 0.75 0.75 0.75
1.2 0.81 0.81 0.81 0.81 0.81 0.81
1.4 0.86 0.86 0.86 0.86 0.86 0.86
1.6 0.89 0.89 0.89 0.89 0.89 0.89
1.8 0.92 0.92 0.92 0.92 0.92 0.92
2 0.94 0.94 0.94 0.94 0.94 0.94
2.2 0.95 0.95 0.95 0.95 0.95 0.95
2.4 0.97 0.97 0.97 0.97 0.97 0.96
2.6 0.97 0.97 0.97 0.97 0.97 0.97
2.8 0.98 0.98 0.98 0.98 0.98 0.98
3 0.99 0.99 0.99 0.99 0.99 0.99
3.2 0.99 0.99 0.99 0.99 0.99 0.99
3.4 0.99 0.99 0.99 0.99 0.99 0.99
3.6 0.99 0.99 0.99 0.99 0.99 0.99
3.8 1 1 1 1 1 1
4 1 1 1 1 1 1
4.2 1 1 1 1 1 1
4.4 1 1 1 1 1 1
4.6 1 1 1 1 1 1
4.8 1 1 1 1 1 1
5 1 1 1 1 1 1
aValues in italics that occur at t/(T1/2) = 2.2 are approximately 95% of X∞{A}. 
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dirty bomb incident. It is assumed here and in the Appendix that the lethality
risk associated with the lavage procedure itself is negligible. The dose increment,
X {t, A}, that occurs before application of lung lavage can be evaluated
using the following relationship, where t = T is the time at which the sin-
gle lung lavage treatment is applied (Scott 2009):
X {T, A} = Xmax{T, A} – Q {T, A}. (10)
The normalized dose increment X {Aalt(T)}, that occurs after lung lavage
is evaluated, using the asymptotic solution presented in Equation 7; how-
ever, A has to be replaced with Aalt(T) (Scott 2009). The subscript alt
stands for altered. The dose rate is evaluated as being reduced (via
lavage) on average by a dose-rate-reduction factor (DRRF) given by DRRF(T),
and the pattern of decline in dose rate afterward is presumed to still be a
negative exponential but with a possibly modified parameter λ1 (which
can be set equal λ when appropriate). The altered dose rate in the lung
just after radiation time t = T is therefore evaluated as follows: 
Aalt(T) = A exp(–λT)/DRRF(T). (11)
For such scenarios, the initial dose rate A in Equation 7 can be
replaced by the altered initial dose rate Aalt(T) and λ is replaced by λ1
when evaluating the increment in the normalized dose that occurs after
lung lavage treatment. This yields the following results (asymptotic solu-
tion) for the indicated increment, X{Aalt(T)}:
X
∞
{Aalt(T)} = (D∞{Aalt(T)}/θ∞) – Q∞{Aalt(T)}. (12)
Please note that λ1 now replaces λ when using Equations 8 and 9 to
evaluate D
∞
{Aalt(T)}and Q∞{Aalt(T)}. The Appendix provides results that
are more general and can be applied to cases where lung lavage is admin-
istered multiple times. The increment X {T, A}, which occurs before lung
lavage, is added to the increment X
∞
{Aalt(T)}, which occurs after lung
lavage, to get the total normalized dose Xpro that is used in evaluating
lethality risk. The subscript pro is used to indicate that protective decor-
poration measures are accounted for (Scott 2009).
The total lethality risk (central estimate) without decorporation coun-
termeasures is indicated as Runpro and is given by the following:
Runpro = 1 – exp{[–ln(2)]X∞{A}
5}. (13)
The subscript unpro stands for unprotected (e.g., no lavage administered).
Table 2 provides risk estimate for Runpro as a function of X∞{A}. The cor-
responding residual risk (Scott 2005) when protective decorporation
Calculating pulmonary-mode lethality risk avoidance
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countermeasures (lavage considered here) are applied at time T is indi-
cated here as Rpro and is given by the following:
Rpro = 1 – exp{[–ln(2)] Xpro
5}. (14)
The shape parameter value of V = 5 in Equations 13 and 14 only applies
to central risk estimation and only for internal irradiation via radionu-
clides (Scott and Hahn 1989). For uncertainty characterization, subjec-
tive lower and upper bounds of 4 and 6 can be applied (Scott and Hahn
1989). The lethality RAV can therefore be evaluated as follows (Scott
2009):
RAV = Runpro – Rpro. (15)
The corresponding equation for the RAP is as follows (Scott 2009):
RAP = RAV/Runpro. (16)
Figure 1 shows the calculated pulmonary-mode-lethality RAVs (cen-
tral estimates) associated with lung lavage when administered to humans
1 h after inhalation exposure to beta- and/or gamma-emitting radionu-
clides in highly insoluble forms. Essentially the same modeling results
(not shown) were obtained for application of lung lavage at 24 h after
inhalation exposure. The variable T1/2 was assigned the hypothetical
B. R. Scott
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TABLE 2. Central estimates of the lethality risk Runpro for the pulmonary mode of death in humans
as a function of the asymptotic value of the normalized dose.
Normalized Dose X
∞
{A} Lethality Risk
0 0
0.4 < 10–2
0.5a 0.02
0.6 0.05
0.7 0.11
0.8 0.20
0.9 0.34
1.0 0.50
1.1 0.67
1.2 0.82
1.3 0.92
1.4 0.98
1.5 0.99
1.6 1.00
aA value of X
∞
{A} = 0.5 (lethality risk < 0.025 for the pulmonary mode) has been used as an esti-
mate of the threshold exposure in radiological risk assessment because of the steepness of the dose-
response curve for the lethality risk (Scott and Hahn 1989). A value of X
∞
{A} = 0.4 (lethality risk <
10–2) may be preferred for the threshold estimate for some applications.
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value of 2000 days for both the pre- and post-lavage periods. Thus λ1 = λ
for this example. Both DRRF(1 h) and DRRF(24 h) were assigned the
hypothetical value of 2. For the indicated hypothetical scenarios, applying
the lung lavage at 24 h after intake would be expected to be as protective
as applying the procedure 1 h after intake. However for a scenario for
which T1/2 = 200 min, this would not be the case as >99% of the radiation
dose would have been delivered by 24 h after radionuclide intake. At 1 h
after intake, only about 19% of the radiation dose would have been deliv-
ered. Applying decorporation therapy at the 1-h time point would there-
fore be expected to eliminate considerable radioactivity from the body
before additional radiation damage is produced. Applying decorporation
therapy at 24 h after radionuclide intake would not be expected to pro-
vide any real benefit because most of the radiation dose would have
already been delivered. 
Figure 2 shows corresponding modeling results (central estimates)
for the RAP for T1/2 = 2000 d when lung lavage is applied at 1 h after
inhalation exposure. Essentially the same modeling results (not shown)
were obtained for application of lung lavage at 24 h after inhalation expo-
sure. For initial dose rates to the lung less than about 0.03 Gy/h, essen-
tially all of the lethality risk would be expected to be avoided as a result
of applying the lavage procedure, irrespective of whether given 1 h or 24
h after intake. The dose-rate zone (for initial dose rates) for which all of
the lethality risk is avoided by the countermeasures applied is called the
green zone (Scott 2009). For initial dose rates to the lung greater than
about 0.07 Gy/h, no benefit of the lavage therapy (single application)
Calculating pulmonary-mode lethality risk avoidance
91
FIGURE 1. Central estimates of the pulmonary-mode-lethality RAV associated with lung lavage when
administered to humans 1 h after inhalation exposure to beta- and/or gamma-emitting radionuclides
in highly insoluble forms. The plotted points correspond to initial dose rates used in the calculations
Results apply to T1/2 = 2000 d.
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would be expected related to preventing death from radiation-induced
damage to the lung. The dose-rate zone for which none of the lethality
risk is avoided by the countermeasures applied (RAP = 0; Rpro = Runpro =
1) is called the red zone (Scott 2009). The dose-rate zone (initial dose rate)
between the green and red zones is where some but not all of the lethal-
ity risk is avoided (i.e., 0 < RAP < 1) and is called the yellow zone (Scott
2009). For single lavage scenarios that are associated with the red zone,
more intensive countermeasures would be warranted (e.g., multiple
lavages and possibly other protective measures).
The dose-rate (initial) boundaries for the green, yellow, and red
zones will depend on the radionuclide decorporation therapy scheme
and exposure scenario. When the HF-model and countermeasure-related
uncertainties are considered, the boundaries will likely become blurred.
Zone boundaries should therefore be considered highly uncertain; how-
ever, new research is needed to address uncertainty-related issues.
The results presented in figures and tables relate to single, negative-
exponential-decaying dose-rate patterns. However, the more general rela-
tionships provided in the Appendix can be used to evaluate the lethality
RAV and RAP and associated green, yellow, and red dose-rate zones
(based on initial dose rate) for a specified scheme for more complex
monotonically decreasing dose rate patterns. 
Some exposure scenarios of interest may involve an initial rise in dose
rate over time followed by a period of steady decreases in dose rate. For
such dose-rate profiles, the increment in the normalized dose that occurs
B. R. Scott
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FIGURE 2. Central estimates of the pulmonary-mode-lethality RAP associated with lung lavage when
administered to humans 1 h after inhalation exposure to beta- and/or gamma emitting radionuclides
in highly insoluble forms. The plotted points correspond to initial dose rates used in the calculations.
Results apply to T1/2 = 2000 d. Dose rate zones (green, yellow, and red) are color coded.
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during the rising dose-rate phase could be evaluated based on taking
small time increments over intervals (t, t + Δt), with average dose rate cal-
culated for each interval. The increment in the normalize dose for each
such interval can be estimated by dividing the interval-specific dose incre-
ment by D50 (evaluated using Equation 3 with the average dose rate for
the interval used in the calculation). The increments in the normalized
dose for the rising phase of dose rate would then add to increments that
arise from the decaying dose rate phase, which can be evaluated as indi-
cated in the Appendix (or alternatively as indicated for the rising dose-
rate phase). Lethality RAV and RAP can then be evaluated in the same way
as outlined above.
The modeling framework presented here could also be applied to
inhalation exposure scenarios that involve combined exposure to alpha-,
beta-, and gamma-emitting radionuclides provided that absorbed dose
was replaced with RBE-weighted dose. Further, competing modes of
death (e.g., pulmonary, hematopoietic, and gastrointestinal) could also
be included. 
The research described here and also in the closely related paper
(Scott 2009) is an extension of much earlier research conducted by the
author. Unfortunately, support for continuing the earlier research disap-
peared some years ago and interest in supporting the type of theoreti-
cal/modeling research presented in these papers has not increased since
that time. Unless more appreciation is develop by the scientific commu-
nity and funding agencies of the important contributions that theoreti-
cal/modeling research (e.g., radionuclide biokinetics/biodistribution,
dosimetry and risk modeling) can make to the advancement of scientific
knowledge related to planning for and managing radiological terrorism
incidents, the next generation of scientist may be devoid of essential
knowledge needed for addressing the types of issues that are addressed in
this paper.
CONCLUSIONS
A theoretical framework was presented for evaluating both the
expected pulmonary mode lethality RAV and RAP associated with lung
lavage therapy for removing inhaled beta/gamma-emitting radionuclides
deposited as a result of a terrorist act involving a dirty bomb. The com-
putational tools provided for evaluating the lethality RAV and RAP should
facilitate planning for and managing such radiological terrorism inci-
dents. RAV and RAP values were evaluated for single-negative exponential
decaying dose-rate patterns to the lung from beta/gamma emitting
radionuclides that are inhaled in highly insoluble forms. The theoretical
framework presented in the Appendix, however, can be applied to any
monotonically decreasing dose rate pattern and could be easily incorpo-
rated into radiological risk assessment software. The framework could
Calculating pulmonary-mode lethality risk avoidance
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also be used to design optimal life saving schemes for application of mul-
tiple lung lavages; however, new research is needed to address uncertain-
ties associated with RAV and RAP evaluations.
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APPENDIX
More Complex, Monotonically Decreasing, Dose-Rate Patterns
A similar approach as described in the main text of this paper can be
employed for any monotonically decreasing, dose-rate pattern to the lung
using the generalized results presented below, where y(t) is the unmodi-
fied dose rate at radiation exposure time t. Relationships are provided
that allow for evaluating small increments in the normalized dose over
consecutive, relatively short radiation exposure time intervals (t, t + Δt).
To address departure from a single, negative-exponential-decaying pat-
tern of dose rate, the parameter λ is replaced by a time-dependent func-
tion λ(t) that allows for a changing rate of radioactivity loss as time
increases. 
To account for the impact on dose rate of applying single or multiple
lung lavages, the dose rate y(t) is adjusted downward by the radiation-
exposure-time-dependent DRRF(t), where the altered radiation absorbed
dose rate z(t) is given by
z(t) = y(t)/DRRF(t). (A1)
Prior to application of any lavage therapy, DRRF(t) = 1; otherwise DRRF(t)
> 1. This leads to the following relationships for the exposure-time-
dependent increment, X {t, Δt, z(t)}, in the normalized dose over the inter-
val (t, t + Δt) (e.g., Δt = 1 day for long-lived radionuclides):
X {t, Δt, z(t)} = {z(t)[1 – exp(–λ(t)Δt]/[λ(t)θ
∞
]} –
(θ1/[λ(t)θ∞2])ln{[z(t)θ∞ + θ1]/[z(t)θ∞ exp(–λ(t)Δt) + θ1]}. (A2)
The decay function λ(t) in the above equation is evaluated as follows:
λ(t) = –[ln{z(t + Δt)/z(t)}]/Δt . (A3)
The use of the function DRRF(t) as indicated in Equation A1 impos-
es a constraint on its values (Scott 2009). The constraint is that DRRF(t2)
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≥ DRRF(t1) when t2 > t1. The constraint is necessary because DRRF(t) acts
on y(t), which relates to the dose-rate pattern when no lung lavage has
been used. Thus, if at time t1 dose rate is reduced by a factor of 2 because
of lung lavage applied, and if at time t2 the already altered dose rate is
reduced also by another factor of 1.5 due to an additional lung lavage,
then DRRF(t1) = 2 and DRRF(t2) = 2 × 1.5 = 3. For this hypothetical exam-
ple, z(t1) = y(t1)/2 and z(t2) = y(t2)/3, where y(t1) and y(t2) relate to the
unmodified dose-rate patterns at times t1 and t2.
It is important that when z(t) is expressed in Gy/h that t be expressed
in hours, θ1 be expressed in Gy2/h, and θ∞ be expressed in Grays. For the
single, negative-exponential-decaying dose-rate pattern A exp(–λt), the
right-hand side of Equation A3 yields λ. 
At the interval for which the last countermeasure is applied at time T,
the asymptotic solutions presented in the main text can be used with the
dose rate Aalt(T) replaced by z(T), which equals y(T)/DRRF(T). The last
increment in the normalized dose will then be expressed as X
∞
{z(T)}. All
of the normalized dose increments then can be added to obtain the total
normalized dose Xpro and applied in Equations 15 and 16 when evaluat-
ing the RAV and RAP. For cases where the long-term retention halftime
in the lung is more than 25 years, using the asymptotic solutions may lead
to overestimation of risk. In such cases Equations A1, A2, and A3 can be
repeatedly used over whatever follow-up time is desired.
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